Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency


Kiykim A., ÖĞÜLÜR İ., Dursun E., Charbonnier L. M., Nain E., Cekic S., ...Daha Fazla

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, cilt.7, sa.8, ss.2790-2815, 2019 (SCI-Expanded) identifier identifier identifier

Özet

BACKGROUND: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established.